Announcements Trials
Browse Landscape

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 144Neoplasms 130Prostatic Neoplasms 81Carcinoma, Non-Small-Cell Lung 79Lung Neoplasms 65Colorectal Neoplasms 46Carcinoma, Hepatocellular 37Stomach Neoplasms 33Multiple Myeloma 28Brain Neoplasms 28Uterine Cervical Neoplasms 27Melanoma 26Pancreatic Neoplasms 25Rectal Neoplasms 24Ovarian Neoplasms 24Head and Neck Neoplasms 23Colonic Neoplasms 23Urinary Bladder Neoplasms 22Hematologic Neoplasms 22Neoplasm Metastasis 21Esophageal Neoplasms 20Carcinoma, Renal Cell 20Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Endometrial Neoplasms 17Recurrence 15Cardiovascular Diseases 15Thyroid Neoplasms 14Lymphoma 14Liver Neoplasms 14

Interventions

tremelimumab 1durvalumab 1atezolizumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Observational × Unresectable Hepatocellular Carcinoma × Clear all
NCT06117891 2026-05-12

REFINE-IO

Bayer

Active not recruiting
300 enrolled
Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT07298538 2025-12-23

Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer

Tianjin Medical University Cancer Institute and Hospital

Active not recruiting
800 enrolled
Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡